


**SCHEMA**

**Study Design:** This is a prospective cohort study that examines the impact of myopenia on toxicity and overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) or newly recognized metastatic recurrence for CRC greater than  $\geq 3$  months (12 weeks) from completion of treatment of non-metastatic CRC planning to or recently started to receive systemic chemotherapy and/or immunotherapy. The study also explores the moderating influence of genetic variation in the association between myopenia and toxicity.



\*CT imaging is performed as part of routine care at baseline and every ~12 weeks during chemotherapy and/or immunotherapy to assess disease response.  
 †Clinical assessments include muscle strength, physical performance, questionnaire assessments, and PRO-CTCAE toxicity assessments.  
 ‡Patients will be followed up to 1 year after diagnosis for survival only.  
 + If unable to engage patient before treatment starts, enrollment is allowed up to four weeks after the start of treatment but must be before Cycle 2 begins.

**Stratification:** In order to ensure a wide range in body composition and a diverse sample of older adults, enrollment will be equally distributed across two age strata: 60-74yo and  $\geq 75$ yo.

**Study Sample:** n=300 (150 patients per age stratum)

**Study Duration:** 3.5 years

**Brief Eligibility Criteria:**

- 1) Older adults (age  $\geq 60$ y) with either newly diagnosed metastatic CRC or newly recognized metastatic recurrence of CRC greater than  $\geq 3$  months (12 weeks) from completion of treatment of non-metastatic CRC.

- 2) Planning to or recently started to undergo immunotherapy and/or 5-FU based chemotherapy as first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan; +/- immunotherapy. Capecitabine is also acceptable. If unable to engage patient before treatment starts, enrollment is allowed up to four weeks after the start of treatment but must be before Cycle 2 begins.
  
- 3) Estimated life expectancy  $\geq 6$  months. Patients enrolled on hospice are ineligible.